FEB 08, 2017 01:30 PM PST

Safety and pharmacokinetic profiles of different buprenorphine SR doses in a rabbit model

C.E. CREDITS: RACE
Speakers
  • Resident Veterinarian, University of Southern California
    Biography
      Dr. Zanetti received his PhD in Biomedical Engineering (emphasis in Stem Cell Biology and Tissue Engineering) from Louisiana State University (Pennington Biomedical Research Center) through his work on novel fracture repair strategies using stem cells and biodegradable scaffolding materials. He later assumed a Staff Scientist position at the McGowan Institute of Regenerative Medicine/Heart and Vascular Institute at the University of Pittsburgh Medical Center where he worked with several animal models to develop innovative cellular therapies for vascular repair following arterial injury related to angioplasty and stenting. Currently, he is completing his residency in laboratory animal medicine (clinical emphasis) at the University of Southern California (USC)/City of Hope (COH). Dr. Zanetti is an active reviewer for a number of peer reviewed journals and is also a member of several professional organizations to include the Academy of Surgical Research, the American Association of Laboratory Animal Science, and the American Veterinary Medical Association. In his talk, Dr. Zanetti will give an overview of his ACLAM-funded research findings on the use of varying doses of buprenorphine sustained release in a rabbit orthopedic model.

    Abstract:

    DATE: February 8, 2017
    TIME: 1:30pm PT, 4:30pm ET

    In rabbits, buprenorphine instant release (IR) is commonly used to alleviate pain, especially in surgical models. However, maintenance of IR therapeutic levels requires redosing which significantly increases unnecessary animal handling, restraint and non-compliance issues post-operatively. The development of sustained-release (SR) formulations of buprenorphine in rabbits to deliver constant levels of the drug with adequate plasma concentration and satisfactory analgesia would greatly improve standard of care. In here, we hypothesized that single subcutaneous administration of at least one of three SR (Buprenorphine SRTM Lab, ZooPharm) concentrations (SRLow - 0.06 mg/kg, SRMedium - 0.15 mg/kg, SRHigh – 0.3 mg/kg - n = 3 animals per group) is associated with up to 72 hours of pain relief and more predictable behavior and pain-associated parameters than IR (0.05 mg/kg BID) in a bilateral rabbit knee defect model. In addition to body weight, fecal output, grimace and lameness (0-4, where 0 = continuous weight bearing, 1 = single limb lameness, 2 = multiple limb lameness, 3 = toe touch – non-weight bearing, and 4 = completely non-weight bearing) scales were assessed and scored before and for 72 hours after surgery. No skin reaction to any of the tested SR concentrations was observed within the study phase. Post-operative assessment also revealed no significant changes in body weight across groups. Compared to IR and SRHigh, daily fecal output assessment was higher in rabbits treated with SRLow and SRMedium. Single limb lameness and signs of pain (grimace scale) were observed only in rabbits treated with IR (24 hours) and SRLow (24-48 hours). In fact, rabbits treated with SRLow also received meloxicam (0.3 mg/kg PO SID) within the first 48 hours. Compared to IR, SRLow and SRHigh single administration of SRMedium had little effect in the fecal output and behavior of rabbits enrolled in the selected surgical model. Rabbits treated with IR, SRHigh and SRMedium had similar PK values during the first post-operative hours. In SRHigh and SRMedium, the plasma concentration of the drug remained within the 1ng/ml mark for at least 48 hours. In conclusion, rabbits treated with one dose of SRMedium at 0.15 mg/kg had similar post-operative outcome to the observed in animals treated twice a day with the gold standard drug (IR) and significantly less adverse effects when compared to the observed in the SRLow and SRHigh groups. Further investigation is needed to validate this pain management protocol in other rabbits orthopedic models.

    Learning objectives: 

    • Provide an overview of buprenorphine SR pharmacokinetics at different doses and over time.
    • Provide an overview of adverse effects and clinical findings after buprenorphine SR administration.

    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    Loading Comments...
    Show Resources